Paracetamol Use and COVID-19 Clinical Outcomes: A Meta-Analysis
Alessandro Bianconi, Enrico Zauli, Clara Biagiotti, Giovanna Letizia Calò, Giovanni Cioni, Gianmarco Imperiali, Vittorio Orazi, Cecilia Acuti Martellucci, Annalisa Rosso, Matteo Fiore, Francesco Sessa · 2024
Read Paracetamol Use and COVID-19 Clinical Outcomes: A Meta-Analysis by Alessandro Bianconi, Enrico Zauli, Clara Biagiotti, Giovanna Letizia Calò, Giovanni Cioni, Gianmarco Imperiali, Vittorio Orazi, Cecilia Acuti Martellucci, Annalisa Rosso, Matteo Fiore, Francesco Sessa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11593956.txt.
Description
During the COVID-19 pandemic, paracetamol was widely advised for fever, sometimes over rival painkillers, and claims flew about whether it helped or harmed patients. Alessandro Bianconi and co-authors pool the evidence in this 2024 meta-analysis, covering one trial and five observational studies with more than 34,000 patients.
Compared with rival drugs or no treatment, paracetamol showed no clear link to death, intensive care, breathing support, or heart and kidney problems. All the studies carried a high risk of bias, so the evidence stays weak. The authors say the data give no reason to prefer one fever drug over another, and better trials are needed.
Catalog record
| CREATOR | Alessandro Bianconi, Enrico Zauli, Clara Biagiotti, Giovanna Letizia Calò, Giovanni Cioni, Gianmarco Imperiali, Vittorio Orazi, Cecilia Acuti Martellucci, Annalisa Rosso, Matteo Fiore, Francesco Sessa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |